Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
Revenue
€ 1,523
Profit
Caution€ -5.2 million
▼ 27% vs 2024
Debts
High€ 6.7 million
▲ 1067% vs 2024
Indigo Diabetes from Gent, company number BE0666442557, closed financial year 2025 with a result of € -5.2 million after tax. For that financial year Indigo Diabetes recorded revenue of € 1,523 and equity of € -1.7 million. Compared with financial year 2024, the result moved from € -4.1 million to € -5.2 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 21, 2026.
What happened at Indigo Diabetes?
What happened at Indigo Diabetes in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Charles-Lambert Beauduin stepped down as director. NBB
- SENSINNOVAT BV stepped down as director. NBB
- Qbic Venture Partners II NV stepped down as director. NBB
- Thuja Capital Management B.V. stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5.2 million. Source: NBB ↗
- Charles-Lambert Beauduin became a director. NBB
- SENSINNOVAT BV became a director. NBB
- Qbic Venture Partners II NV became a director. NBB
In short
From € 7.2 million loss in 2021 to € 5.2 million loss in 2025.
On average € 20,000 of value added per employee in 2024.
A new publication or filing at Indigo Diabetes? We notify you, reason included.
Follow Indigo DiabetesNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Indigo Diabetes is Dictys. It owns 100% of Indigo Medical US Inc. itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Danaè Delbeke
since 2020
Charles-Lambert Beauduin
Director
since 2024 · until 2030
Director · represented by Françoise Chombar
Also active at: Melexis Technologies, BYTEFLIES, Azalea Vision +1 more
since 2024 · until 2030
Director · represented by Sofie Baeten
Also active at: EYED PHARMA, Accelleran, QBIC II FUND ARKIV +9 more
since 2024 · until 2030
Director · represented by Evan Michael Castiglia
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Bollebergen 2B box 5
9052 Gent
Bollebergen 2B box 30
9052 Gent
Active since 17 November 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-UNIXSOLUTIONS Unix-Solutions Network, BE
Domain
Domain
indigomed.com
Registered
2002-05-01
Registrar
Key-Systems GmbH
Expires
2026-05-01
Website info
Features
Security
Network
Details
- Company number
- 0666.442.557
- VAT number
- BE 0666.442.557
- Registered office
- Bollebergen 2B bus 5, 9052 Gent
- Names & denominations
- Indigo Diabetes
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 17 November 2016
- Peppol
- Active · Active since 27 Mar 2026
- Contact
- indigomed.com
- Activities · NACE
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied